dismiss

Clean Sweep Live Auction on Wed. January 30th. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Molecular Imaging Homepage

Former South African nuclear executives to appeal suspensions in court Involves monthslong shutdown of NTP Radioisotopes medical isotope plant

FDA grants Fast Track designation to 64-Cu-Dotatate Used in PET diagnostic exams for suspected neuroendocrine tumors

Progenics Pharmaceuticals selects Curium as European distributor of PyL Imaging agent for visualizing prostate cancer

Editorial takes aim at NRC efforts to lower the bar for nuclear medicine providers 'The NRC has abdicated its role as a protection agency for patients' say authors

GE and VUMC partner to make cancer immunotherapy safer and more precise Five-year collab will yield new AI apps and PET tracers

Top molecular imaging stories of 2018 Last year's biggest news regarding PET and SPECT

Subtle Medical closes RSNA with CE mark and FDA clearance of PET AI solution Speeds up scans by factor of four, enhanced image quality

Siemens unveils syngo Virtual Cockpit software for CT, MR and PET at RSNA Offers remote expert technicians when needed

Total-body PET scanner produces landmark human images First ever simultaneously captured 3-D image of the entire human body

South African NTP Radioisotopes facility reopens following year-long closure Will help alleviate worldwide shortages of Mo-99 and other isotopes

APRINOIA has allowed Celgene to use
its PET tau imaging agent in global
clinical trials

APRINOIA and Celgene partner on promising PET tracer

by John R. Fischer , Staff Reporter
Clinical-stage biotechnology enterprise APRINOIA Therapeutics has given the thumbs-up to Celgene Corporation to make use of its imaging tracer, APN-1607, in global clinical trials.

The Taiwan-based manufacturer will receive annual license and usage fees in exchange for allowing Celgene to use its novel investigational PET agent, which holds the potential for visualizing tau pathology in diverse tauopathies, to support patient selection and efficacy evaluation in its studies.

Story Continues Below Advertisement

Has exclusive distribution agreement with DDD to sell new Camera systems

UMRi provides the very best new & refurbished gamma cameras, quality parts &repair services. We also rebuild & replace camera detectors, move camera systems across town or across the country. Call us at 888-239-3510



"We are excited to collaborate with Celgene, one of our most valued global partners," Ming-Kuei Jang, CEO of APRINOIA, said in a statement. "With APN-1607's unique properties, we believe it can offer our partners a valuable tool to validate therapeutic candidates for diverse neurodegenerative disorders, including multiple tauopathies.”

Evaluated clinically in the U.S., Japan, Taiwan and mainland China, APN-1607 holds the potential to visualize tau pathology in diverse tauopathies, such as mild cognitive impairment; dementia due to Alzheimer’s disease; corticobasal degeneration syndrome; and progressive supranuclear palsy (PSP). The FDA recently granted orphan drug designation status to the agent for PSP.

The agent is currently deployed worldwide by APRINOIA at a number of academic medical centers, which are able to apply it to obtain a better understanding of the natural history of tau pathology in rare tauopathies as well as Alzheimer’s.

APRINOIA is also leveraging its use in the company’s tau therapeutic program due to the value it offers in the development of effective treatments for such diseases.

The development of imaging agents for visualizing tau is currently a high priority among many molecular imaging researchers. One team, for instance, recently published their findings on their work in identifying 18F-R0-948 as a promising second-generation PET tracer for imaging and measuring such pathology.

Additionally, Cerveau Technologies announced, this past summer, plans to expand its production network to enhance access and opportunities in research for [18F]MK-6240, a novel contrast agent utilized in PET scans to assess the status and progression of neurofibrillary tangles (NFTs) within the brain as part of several neurodegenerative conditions including Alzheimer’s disease.

“This expansion of the biomarker production network underscores our commitment to the broader scientific research community and our support of the industry’s initiatives to combat neurodegenerative disorders,” Rick Hiatt, president and chief executive officer of Cerveau Technologies, said in a statement at the time.

The specific costs of license and usage fees to APRINOIA were not disclosed.

APRINOIA declined to comment. Celgene did not respond for comment.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED